Genmab(GMAB) - 2023 Q3 - Quarterly Report

Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2023 November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights "With regulatory approvals in Japan and Europe, EPKINLY/TEPKINLY is the first Genmab- owned medicine to become available to patients outside of the United States. In addition to being an important milestone for Genmab, these approvals mark an important milestone for patients in these territories who are in need of ...